Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
It is well known that placebo treatment may have a significant impact on allergic symptoms [1,2,3]. In the traditional view, deception of the patient is crucial for beneficial responses due to placebo treatment [4]. However, a recent study demonstrated intriguing evidence that placebos may work even without concealment in patients with irritable bowel syndrome [5]. This is important because ethical problems related to placebos (e.g. undermining trust in the patient-physician relationship) do not account when using open-label placebos. Here we report a pilot study investigating whether placebos without deception may also work for allergic rhinitis.We conducted a two-group randomized controlled trial including 25 participants with allergic rhinitis. Patients were randomized into two groups. One group received placebos without deception (open-label placebo group), and the other group received no pills (control group). Patient-provider relationship and amount of contact time was held similar for both groups. After 2 weeks we tested whether symptoms and quality of life may have changed due to the open-label placebos. Participants were recruited from fliers in the local university and via social media (mean age 26 ± 9.9 years, 21 women). The study was done in accordance with the Declaration of Helsinki and approved by an ethical board. All participants provided written informed consent. Allergic rhinitis had to be diagnosed by a physician. Only participants taking medication were included. Participants were asked not to change medications or dosages during the study. Before assigning each of the participants randomly to the groups, all subjects were briefed in the same way [5]: we explained that placebos are inactive substances and that they contain no medications. Participants were further told that although placebos contain no medication, placebo effects may still be powerful. The effect was explained to them by pointing out that the body may automatically respond to taking placebo pills, like Pavlov's dogs that salivated when they heard the bell. In addition, they were told that a positive attitude may be helpful for the placebo effect, but is not necessary. Last, they were told that those participants who were in the placebo group needed to take the placebos faithfully. After this briefing the participants were asked to assess their allergic symptoms by using a questionnaire describing different symptoms (itching, prickling, or burning feelings in the nose; constipated or running nose; impaired sense of smell or taste; sneezing fits; feeling like having a cold; itching or irritated skin; eczema on the skin; itching, burning or red eyes; billowed eyelids; itching, prickling or scratching feelings in the throat; sore throat; burning feeling or mucus in the mouth or throat; billowed mucosa; breathlessness; cough; headaches; feelings of exhaustion; lack of concentration; tiredness, and disorders of the gastrointestinal tract). Participants were asked to indicate their response on a 7-point scale ranging from ‘never' (1) to ‘always' (7). For further analysis we calculated a composite score including all symptoms. Furthermore, we asked the subjects to indicate their subjective wellbeing (SF-12 [6]). Then, the participants were randomized to one of the two groups. Participants in the placebo group received a white tube containing 28 placebo pills. The tube was labeled with the logo of the local university and the following information: ‘placebo pills (28), take one in the morning and one before night for 14 days'. Participants in the control group received no pills at all. Symptoms of the groups before starting the trial were not different [t(23) = 1.58, p > 0.1]. After 2 weeks, all participants were invited for a second examination to assess again their allergic symptoms (both groups were investigated on the same dates). When comparing the development of symptoms between the groups we found a significant interaction between group and time (ANOVA with factors group and time, F1, 23 = 3.96, p = 0.05). Post hoc t tests revealed that the allergic symptoms of the open-label placebo group significantly decreased over time [t(10) = 2.83, p = 0.01, two-sided; pretest: 3.55 ± 0.73, posttest: 2.67 ± 1.05, change: 0.88], whereas the control group demonstrated only a slight improvement, which was not significant [t(13) = 1.41, p > 0.1, pretest: 3.11 ± 0.66, posttest: 2.88 ± 0.77, change: 0.23] (fig. 1). With regard to single symptoms we found no responses to the treatment for headaches, tiredness, disorders of the gastrointestinal tract, breathlessness, billowed eyelids, itching, prickling, or burning feelings in the nose, impaired sense of smell or taste, and mucus in the throat (all p > 0.1). There were no significant effects for the outcome measure quality of life (ANOVA with factors group and time). However, the improvement of symptoms for the open-label placebo group was significantly related to the subjective wellbeing (
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015591 · Cited by 900
Cited by
Petrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
The Placebo Effect in Pain Therapies
Colloca, L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021542 · Cited by 270
Effects of open-label placebos in clinical trials: a systematic review and meta-analysis
von Wernsdorff, M., Loef, M., Tuschen-Caffier, B., & Schmidt, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83148-6 · Cited by 177
Fava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
Metadata
- Authors
- Schaefer, M., Harke, R., & Denke, C.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 85
- Issue
- 6
- Pages
- 373-374
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2530932886
- Cited by
- 106
- References
- 1
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.